NASDAQ:FTH Sensei Biotherapeutics Q3 2025 Earnings Results & Report $11.58 -1.77 (-13.28%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Sensei Biotherapeutics beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$3.62 versus the -$4.11 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Sensei Biotherapeutics EPS ResultsActual EPS-$3.62Consensus EPS -$4.11Beat/MissBeat by +$0.49One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersSensei Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Sensei Biotherapeutics Q3 2025 Earnings FAQ Did Sensei Biotherapeutics beat earnings estimates for Q3 2025? Sensei Biotherapeutics (NASDAQ:FTH) reported earnings of -$3.62 per share for Q3 2025, beating the consensus estimate of -$4.11. The report was announced on Friday, November 14, 2025. Sensei Biotherapeutics Earnings HeadlinesFaeth Therapeutics to Participate in Upcoming November Investor ConferencesNovember 11 at 7:30 AM | businesswire.comFaeth Therapeutics plummets 45% — here's what happenedNovember 10 at 5:54 PM | msn.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 12 at 1:00 AM | Behind the Markets (Ad)Analyst Firms Have Faith In Faeth TherapeuticsNovember 5, 2026 | seekingalpha.comFaeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesNovember 3, 2026 | businesswire.comFaeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against GedatolisibOctober 23, 2026 | businesswire.comSee More Sensei Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email. Email Address About Sensei BiotherapeuticsSensei Biotherapeutics (NASDAQ:FTH) is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products. Based in the United States, Sensei has focused its work on oncology research and development. Its approach has included developing antibody-based medicines and other immunotherapies for potential use alone or alongside existing cancer treatments.View Sensei Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
